CN105968174A - Avian influenza H9N2 subtype virus HA protein linear antigen epitope polypeptide - Google Patents
Avian influenza H9N2 subtype virus HA protein linear antigen epitope polypeptide Download PDFInfo
- Publication number
- CN105968174A CN105968174A CN201610321844.5A CN201610321844A CN105968174A CN 105968174 A CN105968174 A CN 105968174A CN 201610321844 A CN201610321844 A CN 201610321844A CN 105968174 A CN105968174 A CN 105968174A
- Authority
- CN
- China
- Prior art keywords
- avian influenza
- epitope polypeptide
- antigen epitope
- virus
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/11—Orthomyxoviridae, e.g. influenza virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
Abstract
The invention provides avian influenza H9N2 subtype virus HA protein linear antigen epitope polypeptide. The avian influenza H9N2 subtype virus HA protein linear antigen epitope polypeptide has an amino acid sequence which is as shown in SEQ ID NO: 1. The avian influenza H9N2 subtype virus HA protein linear antigen epitope polypeptide provided by the invention is used for preparing a product for detecting avian influenza viruses. Basis is provided for further establishing a method for efficiently detecting avian influenza through authentication on the avian influenza H9N2 subtype virus HA protein linear antigen epitope polypeptide, and meanwhile, a foundation is laid for researching the structure and the function of HA protein.
Description
Technical field
The invention belongs to animal medicine molecular immunology technical field, particularly relate to a kind of Avian Influenza Virus H9N2 HA
The linear antigen epitope polypeptide of albumen and application thereof.
Background technology
Bird flu H9N2 subtype virus (AIV) belongs to influenza A virus, be by influenza A cause the one of birds from
Respiratory system is to the infectious disease of the multiple symptoms such as severe total septicemia, and International Office of Epizootics is set to category A infectious disease.1966
Year HoMee is separated to the first strain H9N2 subtype avian influenza virus, afterwards H9N2 hypotype fowl from the turkey suffering from gentle respiratory tract disease
Influenza is the most popular, within especially 1994～1999, worldwide causes huge economic loss.
1994, China's reported first was separated to H9N2 subtype avian influenza from Ji Qunzhong, occurs relevant report the most successively.Autumn in 1998
H9N2 subtype avian influenza occurs in China, has i.e. swept across most of province in short 2 months, and because its virulence is more weak, mortality rate does not has
There are H5N1, H7N1 high, and do not cause enough attention.Stablize it has been investigated that H9N2 hypotype defines one in China's Mainland
Subbreed, this not only has a significant damage to aviculture, and serious threat human health.And study and show, H9N2 hypotype portion
The pathogenicity dividing epidemic strain substantially makes a variation, and especially to broiler chicken, mortality rate can reach more than 30%；Egg to egg-laying peak
Chicken, its egg drop reduction amplitude is big, recovers difficulty.
Study on etiology shows, H9N2 subtype avian influenza virus belongs to the influenza A of orthomyxoviridae family, its genome
For sub-thread strand RNA, virion has pleomorphism, and typical influenza A is ball-type, a diameter of 80-120nm.Virus
Particle is about made up of 0.8-1.1%RNA, 0-75% protein, 20-24% lipid and 5-8% carbohydrate.H9N2 gene
Group is constituted (PB1, PB2, PA, HA, NP, NA, M, NS) by 8 RNA sections, is separately encoded 10 gene outcomes, including PB1,
PB2, PA, HA, NP, NA, M1, M2 and HA, NS2 albumen, wherein PB1, PB2, PA, HA, NP, NA, M1 are structural protein, M2 and
HA, NS2 are non-structural protein.Adventitia haemagglutinin antigen HA and the difference of neuraminidase antigen NA, avian influenza according to virus
Poison has 16 kinds of HA hypotypes (H1-H16) and 9 kinds of NA hypotypes (N1-N9) at present, can form various serotype between different HA and NA
Bird flu virus, such as: H9N2, H5N1, H3N2 etc., the antibody of a kind of hypotype can only neutralize the virus antigen of homotype, different sub-
The antigen of type is without cross-protection.
Whole world epitope group development in recent years speed is increasingly faster, and substantial amounts of epitope is analyzed and signs out
Come, provide extremely important Research foundation for the exploitation of diagnostic medicine, epi-position group, antibody group and functional antibodies.At present,
Identified influenza antigen epi-position majority derives from the Strain such as H1N1, H3N2 and H5N1, and to H9N2 subtype avian influenza
Epitope research be substantially among blank, therefore the present inventor has carried out the appraisal of HA epitope, to energy
Enough methods for setting up efficient detection bird flu further provide theoretical foundation.
Summary of the invention
The technical problem to be solved is to provide avian influenza virus HA protein cell antigen epitope polypeptide, thus more
Mend the deficiencies in the prior art
The avian influenza virus HA protein antigen epitope polypeptide of the present invention, it is characterised in that described antigen epitope polypeptide has
Aminoacid sequence as shown in SEQ ID NO:1.
Further, present invention also offers the nucleotide sequence of antigen epitope polypeptide described in coding.
In the present invention, it is preferred to, described nucleotide sequence is as shown in SEQ ID NO:2.
Expression vector containing described nucleotide sequence and the host cell containing described expression vector also should belong to
Scope of the present invention.
Antigen epitope polypeptide of the present invention is for preparing the goods of detection bird flu virus.
Avian influenza virus HA protein B cell antigen epitope polypeptide be accredited as the side setting up efficient detection bird flu further
Method provides foundation, and the most also the 26S Proteasome Structure and Function for research HA albumen is laid a good foundation.
Accompanying drawing explanation
Fig. 1: for synthesis bird flu virus H9N2 and protein B cell antigen epitope polypeptide compares chicken with SPF, bird flu is exempted from
Epidemic disease chicken and avian influenza infection chicken serum combine ELISA reaction result figure.
Detailed description of the invention
The bird flu H9N2 subtype virus immunity BALB/c mouse that the present invention concentrates and purifies with PEG precipitation ultracentrifugation, uses
Restructuring HA albumen, influenza virus purification and the HI experiment expressed are screened, and prepare 3 strain energy stably excreting anti-HA specificitys altogether
The hybridoma cell strain of antibody.The method of further Western blot qualification and IFA identifies can be with eukaryotic expression system
The 3 strain MAbs that the HA protein-specific of system transient expression combines, demonstrate the specificity of MAbs, are respectively designated as HA Mab
3A4D6,1A2B7 and 2B6D9.Utilize phage display peptide library technology sieve HI titer the highest select anti-HA Mab 3A4D6 gram
Grand, 10 positive colonies of final acquisition, obtain 8 peptide sequences after order-checking,
Below in conjunction with specific embodiment further describe the present invention, advantages of the present invention and feature will be with describe and
Apparent.But these embodiments are only exemplary, it is not ERSKIEFVK to this its consensus sequence, with strain used
HA encoding histone amino acid alignment finds that it has 7 amino acid sites to mate completely with aa507～aa515, prompting507ERQKIEGVK515A linear epitope for HA antigen.The scope of invention constitutes any restriction.Those skilled in the art should
It is understood by, the details of technical solution of the present invention and form can be modified lower without departing from the spirit and scope of the present invention
Or replace, but these amendments and replacement each fall within protection scope of the present invention.
The qualification of embodiment 1 bird flu H9N2 subtype virus linear epitope
1 material and method
1.1 major experimental material and laboratory animals: SP2/0 cell is preserved by applicant place laboratory；Express AIV
(H9N2) the recombiant plasmid Pet28a-HA of HA is built by this laboratory；AIV (H9N2) virus is preserved by this laboratory；SPF chicken
Embryo is purchased from Cimmeria；6～8 week old SPF BALB/c female mices purchase Beijing medical college Experimental Animal Center.
1.2 main agents: PEG6000 (Merck), sucrose (Shanghai traditional Chinese medicines), Freund's complete adjuvant and Freund are not exclusively helped
Agent (SIGMA), Rabbit anti mouse-HRP (SIGMA), Rabbit anti mouse-FITC (SIGMA), phage display technology
Show peptide storehouse test kit (NEB)
The virus of 1.3 purification and qualification: inoculate after bird flu virus normal saline 1:10000 times of preservation is diluted
In 10 instar chicken embryos, each egg injection 0.2ml, (35+1) DEG C, 60% humidity after cultivating three days Embryo Gallus domesticus is placed in 4 DEG C overnight, receive
Its allantoic fluid measures its hemagglutination activity.Centrifuging and taking supernatant after multigelation three times, is slowly stirred addition NaCl to 0.5mol/L, then
Stirring adds the PEG6000 of isopyknic 10%, and 4 DEG C overnight.8000rpm is centrifuged 30min and takes precipitation, adds original volume 10%
After PBS suspendible, 4 DEG C overnight.8000rpm centrifuging and taking supernatant with 20%, 40%, 60% sucrose 18000rpm density gradient centrifugation
Collecting virus layer between 2h, 40%-60%, addition PBS rear 18000rpm in right amount is centrifuged 2h and takes precipitation PBS suspendible.Measure HA-HI test
And protein concentration, after subpackage ,-20 DEG C save backup.SPF chick embryo allantoic liquid ibid operates retention negative controls simultaneously.
1.4 animal immunes: virus after purification and the adjuvant female Mus of equal-volume mixed immunity, immunity uses intramuscular injection
Mode, dosage is 50 μ g/, every immunity in 2 weeks once, immunity 3 times.3 exempt from rear 7d docking blood sampling, utilize HA recombiant protein to be coated
Elisa plate survey serum titer.Before fusion, 3d selects the mouse peritoneal injection 100ug booster immunization that serum titer is the highest.
The foundation of 1.5 HA indirect ELISA methods: indirect ELISA operation routinely, utilizes square formation method to determine the screening of MAb
Condition.HA recombiant protein concentration after purification is 1mg/ml, be coated liquid to its carry out 1:10,1:50,1:100,1:200,1:
500 times of dilutions, carry out 1:500,1:1000,1:2000,1:4000,1:8000 times with PBS to positive serum and dilute.With positive hole
OD value closest to 1, P/N value more than 2 albumen and serum-concentration as best effort concentration.
The foundation of 1.6 AIV virus protein indirect ELISA methods: indirect ELISA operation routinely, utilizes square formation method to determine
The screening conditions of MAb.HA recombiant protein concentration after purification is 1mg/ml, be coated liquid to its carry out 1:10,1:50,1:100,
1:200,1:500 times dilutes, and with PBS, positive serum is carried out 1:500,1:1000,1:2000,1:4000,1:8000 times and dilutes.
With positive hole OD value closest to 1, P/N value be more than 2 albumen and serum-concentration as best effort concentration.
The preparation of 1.7 hybridomies: the cell after mouse boosting cell and SP2/0 are merged with HA indirect ELISA and
AIV virus protein indirect ELISA Parallel testing, takes double positive clone's limiting dilution assay and carries out clone's cultivation, clone 3～4
The hybridoma of stably excreting specificity MAb is obtained after secondary.The positive cell strain supernatant HI of acquirement is tested and screens, take
The clone having HI titer carries out building strain.
The preparation of 1.8 MAb ascites: according to a conventional method, takes the female Blab/C mouse peritoneal injecting fluid stone of 6-8 week old
Wax 0.5ml/ only, injects 1*10 after 1 week6Individual cell/only, gained ascites 5000rpm centrifuging and taking supernatant ,-20 DEG C of subpackages preserve.Point
Jian Ce HI titer, indirect ELISA titer and subgroup identification.
1.9 Western blot identify: SDS-PAGE method routinely: 6% concentrates glue, and 15% separation gel carries out electrophoresis
After, pvdf membrane, 15V transfers 0.5h, after being closed overnight by the pvdf membrane after transfer, after ascites 1:200 being diluted after PBST washing
Hatching 100min for 37 DEG C, add two and resist 37 DEG C to hatch 60min after washing, after washing, DAB lucifuge colour developing 15-30min is clear to band.
Taking Pictures recording after distilled water wash.
1.10 IFA identify: by chick embryo fibroblast (CEF) through 0.5% trypsinization, add 24 porocytes and cultivate
Plate, cultivates 24h in 37 DEG C of incubators；Virus is diluted postoperative infection CEF according to 1:100/1:1000/1:10000, occurs after 36h
Significantly cytopathy, CEF becomes round, and plaque occurs, carries out cell and fixes, and adds the acetone 1ml/ hole of pre-cooling, and room temperature stands
10min, PBS wash one time, add the ascites dilutions 200ul/ hole of 1:100 dilution, place 30min, PBS and wash in 37 DEG C of water-baths
Wash three times, add fluorescence two anti-100ul/ hole, fluorescence microscopy Microscopic observation after washing.
1.11 MAb identify the Preliminary Identification of epitopes: according to the Phage Display Peptide description of NEB company to MAb pair
The epitope answered is identified.With 100 μ g/ μ l MAb wrapper sheet (150 μ l/ hole), 4 DEG C overnight.0.1%TBST washes plate and closes
After, every hole adds the phage of 4 × 1010pfu, elution of bound phage expanding after hatching 1h.Measure phage before and after amplification
Titre, in case lower whorl screening use.When second and third takes turns elutriation, the wrapper sheet concentration of MAb is down to 75 μ g/ μ l, 50 μ g/ μ l respectively,
TBST concentration increases to 0.3%, 0.5% respectively, third round elutriation product after having surveyed titre random picking phage clone expand
Increase.With 100 μ g/ μ l MAb wrapper sheet (150 μ l/ hole), after amplification, phage anti-carries out Phage-ELISA reaction as one.For
Reaction the person of being positive check order.
Table 1, positive bacteriophage sequencing result are analyzed and H9N2HA sequence alignment table
●For different amino acids sequence
Contrast shows that its concensus sequence is ERSKIEFVK, with the HA encoding histone aminoacid sequence of strain used
Row comparison finds that it has 7 amino acid sites to mate completely with aa507～aa515, prompting
507ERQKIEGVK515A linear epitope for HA antigen.
The bird flu H9N2 subtype virus linear antigen epitope polypeptide of HA albumen of embodiment 2 present invention is indirect at bird flu
Application in ELISA method detection influenza virus:
Synthesis polypeptide ERQKIEGVK is diluted to 0.1 μ g/ μ l, is coated elisa plate, with SPF chicken serum according to 100 μ l/ holes
Resist as one as comparison, avian influenza vaccine immune chicken serum and avian influenza chicken serum, rabbit anti-chicken HRP-IgG conduct
Two resist, and carry out indirect ELISA checking, after OPD colour developing, read 490nm and locate OD value in microplate reader, result display synthesize polypeptide and
After infected chicken seroreaction, its OD value is apparently higher than matched group and immune group.Illustrate that this synthesis polypeptide and infected chicken serum have combination
Characteristic, it is possible to for diagnosis and the detection of bird flu virus.
Claims (6)
1. an avian influenza virus antigen epitope polypeptide, it is characterised in that the aminoacid sequence of described antigen epitope polypeptide is SEQ
ID NO:1。
2. a nucleotide, it is characterised in that the described antigen epitope polypeptide described in polynucleotide encoding claim 1.
3. nucleotide as claimed in claim 2, it is characterised in that the sequence of described nucleotide is SEQ ID NO:2.
4. a recombinant expression carrier, it is characterised in that described recombinant expression carrier carries the nucleoside described in claim 2
Acid.
5. a recombinant host cell, it is characterised in that described recombinant host cell converts/transfects has the right described in requirement 4
Recombinant expression carrier.
6. the application in the goods of preparation detection bird flu virus of the antigen epitope polypeptide described in claim 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610321844.5A CN105968174A (en) | 2016-05-13 | 2016-05-13 | Avian influenza H9N2 subtype virus HA protein linear antigen epitope polypeptide |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610321844.5A CN105968174A (en) | 2016-05-13 | 2016-05-13 | Avian influenza H9N2 subtype virus HA protein linear antigen epitope polypeptide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105968174A true CN105968174A (en) | 2016-09-28 |
Family
ID=56955701
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610321844.5A Pending CN105968174A (en) | 2016-05-13 | 2016-05-13 | Avian influenza H9N2 subtype virus HA protein linear antigen epitope polypeptide |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105968174A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101353371A (en) * | 2007-07-27 | 2009-01-28 | 厦门大学 | H5 subtype avian influenza virus neutralization epitope peptide mimics and uses thereof |
| CN101885757A (en) * | 2009-05-11 | 2010-11-17 | 中国医学科学院基础医学研究所 | Avian influenza hemagglutinin, epitope peptide, monoclonal antibodies for resisting avian influenza hemagglutinin and epitope peptide, and applications of monoclonal antibodies |
| CN104804099A (en) * | 2015-04-01 | 2015-07-29 | 广州谱泰生物技术有限公司 | Recombinant H9N2 subtype avian influenza enhanced multi-epitope vaccine |
-
2016
- 2016-05-13 CN CN201610321844.5A patent/CN105968174A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101353371A (en) * | 2007-07-27 | 2009-01-28 | 厦门大学 | H5 subtype avian influenza virus neutralization epitope peptide mimics and uses thereof |
| CN101885757A (en) * | 2009-05-11 | 2010-11-17 | 中国医学科学院基础医学研究所 | Avian influenza hemagglutinin, epitope peptide, monoclonal antibodies for resisting avian influenza hemagglutinin and epitope peptide, and applications of monoclonal antibodies |
| CN104804099A (en) * | 2015-04-01 | 2015-07-29 | 广州谱泰生物技术有限公司 | Recombinant H9N2 subtype avian influenza enhanced multi-epitope vaccine |
Non-Patent Citations (3)
| Title |
|---|
| 刘洪云: "《猪病防治技术手册》", 31 July 2009 * |
| 李乙江: "H5N1 和H9N2 禽流感病毒HA 抗原性对比分析和基因免疫研究", 《四川畜牧兽医》 * |
| 王金良: "噬菌体展示技术在动物病毒抗原表位筛选中的应用", 《中国畜牧兽医学会家畜传染病学分会第八届全国会员代表大会暨第十五次学术研讨会论文集》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9499850B2 (en) | Modified influenza virus for monitoring and improving vaccine efficiency | |
| Pushko et al. | Influenza virus-like particle can accommodate multiple subtypes of hemagglutinin and protect from multiple influenza types and subtypes | |
| CN101448520B (en) | Avian influenza viruses, vaccines, compositions, formulations, and methods | |
| KR20120132506A (en) | Vaccines for use in the prophylaxis and treatment of influenza virus disease | |
| CN102406931B (en) | Pandemic influenza virus split vaccine | |
| CN106559986A (en) | Multivalence influenza virus-like particles (VLP) and its purposes as vaccine | |
| CN107281478A (en) | Influenza vaccines | |
| CN101643721A (en) | Broad-spectrum safe anti influenza A virus vaccine for animals | |
| Rauff et al. | Evolutionary consequences of a decade of vaccination against subtype H6N2 influenza | |
| Zhong et al. | The antigenic drift molecular basis of the H5N1 influenza viruses in a novel branch of clade 2.3. 4 | |
| Prabakaran et al. | Cross-protective efficacy of baculovirus displayed hemagglutinin against highly pathogenic influenza H7 subtypes | |
| Sreenivasan et al. | Host Range, Biology, and Species Specificity of Seven-Segmented Influenza Viruses—A Comparative Review on Influenza C and D | |
| Peng et al. | Protective efficacy of an inactivated chimeric H7/H5 avian influenza vaccine against highly pathogenic avian influenza H7N9 and clade 2.3. 4.4 H5 viruses | |
| CN105968174A (en) | Avian influenza H9N2 subtype virus HA protein linear antigen epitope polypeptide | |
| CN103333224B (en) | Avian influenza virus NS1 protein B cell epitope polypeptide and applications thereof | |
| CN109563138A (en) | The modification of modified influenza hemagglutinin polypeptide | |
| CN107064499B (en) | Avian influenza virus nucleoprotein antigen epitope polypeptide and its colloid gold test paper box | |
| Suzuki et al. | Potency of an inactivated influenza vaccine prepared from A/duck/Hokkaido/162/2013 (H2N1) against a challenge with A/swine/Missouri/2124514/2006 (H2N3) in mice | |
| Xu et al. | Hemagglutinin amino acids related to receptor specificity could affect the protection efficacy of H5N1 and H7N9 avian influenza virus vaccines in mice | |
| Oxford et al. | Influenza—the chameleon virus | |
| CN107384875A (en) | Chimeric the newcastle Disease poisonous carrier H7 live vaccines Candidate Strain and its construction method for overcoming chicken Newcastle disease maternal antibody to influence | |
| Reneer | H2 Influenza Human Serological Assessment and Development of Broadly Cross-Reactive H2 Influenza Pre-Pandemic Vaccines | |
| Muth | Viral shedding and antibody response of mallard ducks to avian influenza viruses | |
| Heiden | Evaluation of Self-Adjuvanting M2e Vaccine Efficacy in Response to Influenza A Virus Challenge | |
| Li | Development of competitive ELISA for detection of N1 and N2 antibodies against influenza virus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160928 |
|
| RJ01 | Rejection of invention patent application after publication |